Bessemer Group
ATOS icon

Bessemer Group’s Atossa Therapeutics ATOS Stock Holding History

Bessemer Group’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+6
New +$27 ﹤0.01% 2521

Other funds holding ATOS

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bessemer Group's ATOS Position: Q2 2026 in Review

Bessemer Group opened a new position in Atossa Therapeutics (ATOS) in Q2 2026: 6 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2521 among its holdings.

31 funds tracked by Wall St. Rank hold ATOS as of Q2 2026.

  • Bessemer Group held 6 shares of Atossa Therapeutics worth $0 as of Q2 2026.
  • Atossa Therapeutics was a new Bessemer Group position in Q2 2026.
  • Atossa Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2521 holding.
  • 31 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.